3.8 Article

Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients =80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Geriatrics & Gerontology

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study

Susann Varano et al.

Summary: This subpopulation analysis from the EMPOWUR study demonstrated that once-daily vibegron 75 mg showed rapid onset and robust efficacy compared to placebo in OAB patients aged >= 65 and >= 75 years, with a generally safe and well-tolerated profile consistent with the overall population results.

DRUGS & AGING (2021)

Article Pharmacology & Pharmacy

Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder

Shizuo Yamada et al.

Summary: Mirabegron inhibits muscarinic receptors in rat bladder and induces relaxation of detrusor smooth muscle. Predicted muscarinic receptor occupancy in human bladder after oral administration of mirabegron ranges from 37% to 76%.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)

Article Urology & Nephrology

Muscarinic receptor binding activity in rat tissues by vibegron and prediction of its receptor occupancy levels in the human bladder

Shizuo Yamada et al.

Summary: The study revealed the inhibitory effects of vibegron on muscarinic receptors in the rat bladder and other tissues, with varying binding affinities in different locations. By using rat bladder receptor binding affinity, occupancy levels of muscarinic receptors in the human bladder after oral administration of vibegron were predicted.

INTERNATIONAL JOURNAL OF UROLOGY (2021)

Article Urology & Nephrology

Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?

Cora Fogaing et al.

CURRENT UROLOGY REPORTS (2020)

Article Nutrition & Dietetics

Aging well: an update

Hiroko Akiyama

NUTRITION REVIEWS (2020)

Article Pharmacology & Pharmacy

Vibegron: First Global Approval

Susan J. Keam

Article Chemistry, Medicinal

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

Scott D. Edmondson et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

Article Urology & Nephrology

An Overactive Bladder Symptom and Health-Related Quality of Life Short-Form: Validation of the OAB-q SF

Karin S. Coyne et al.

NEUROUROLOGY AND URODYNAMICS (2015)

Review Urology & Nephrology

Long-Term Adherence to Antimuscarinic Therapy in Everyday Practice: A Systematic Review

Paul W. Veenboer et al.

JOURNAL OF UROLOGY (2014)